The American Society of Clinical Oncology published three clinical practice guidelines for the prevention and management of neuropathy, fatigue, depression, and anxiety.
A phase I single-arm study of LDK378 (ceritinib) demonstrated an overall response rate of 58 percent in patients with ALK-positive non-small cell lung cancer. Patients who received 400 mg or higher of LDK378 per day had a median progression-free survival of seven months.
Neratinib combined with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.
Top-line results of a phase III trial evaluating talimogene laherparepvec in melanoma failed to meet its secondary endpoint of overall survival. The trial had previously reached its primary endpoint of durable response rate.
Last year, a phase III trial demonstrated Nexavar (sorafenib) tablets significantly extended progression-free survival in locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
Top-line results from a phase III trial evaluating the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet its primary endpoint of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer when compared to docetaxel/prednisone alone.
FDA approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma.
Last week, a blistering opinion piece on The New York Times editorial page focused on the coziness of the relationship between the American Cancer Society and Walgreens. The piece initially triggered criticism by ACS officials, but then—with no fanfare whatsoever—the society’s CEO called on the drug store chain, as well as others, to stop selling tobacco […]
CCOP Letter to VarmusThe letter to Varmus was signed by 56 of the 64 CCOP PIs.
The Gap OpensMany doctors who participate in CCOPs commit money from their practices to this endeavor. Institutions, too, end up having to throw in subsidies.
